Tag: Patents
Cancer Test Patent Dispute Leads to Preliminary Injunction Against NeoGenomics
July 12, 2024
Natera, Inc. v. NeoGenomics Labs., Inc Authored by: Jeremy J. Gustrowsky A recent decision from the Federal Circuit highlights the importance of patent rights in the competitive world of cancer diagnostics. Natera, Inc., a company specializing in oncology testing, secured…
Read MoreCourt Reverses Broad Trade Secret Injunction in Insulin Pump Dispute
June 17, 2024
Insulet Corp. v. EOFlow, Co Authored by: Jeremy J. Gustrowsky A recent decision highlights the high bar companies must clear to win a preliminary injunction in trade secret cases. Insulet Corp., a maker of wearable insulin pumps, had obtained a…
Read MorePatent Time Limits: When Amending Claims Can Cost You the Patent
May 23, 2024
Speck v. Bates Authored by: Jeremy J. Gustrowsky A recent Federal Circuit decision highlights the importance of timing and claim amendments in patent interference proceedings. The dispute centered on a drug-coated balloon catheter, with Ulrich Speck and Bruno Scheller challenging…
Read MoreDefendants Can’t Recover IPR Fees or Hold Opposing Counsel Liable in Patent Disputes
May 20, 2024
Dragon Intell. Prop. LLC v. DISH Network L.L.C Authored by: Jeremy J. Gustrowsky A recent appellate decision clarifies the limits of attorney fee awards in patent disputes, especially when a defendant prevails by invalidating a patent through inter partes review…
Read MorePatent Owners Must Show Investments Tied to Each Patent to Succeed at the ITC
May 8, 2024
Zircon Corp. v. Int’l Trade Comm’n Authored by: Jeremy J. Gustrowsky A recent decision highlights the importance of how patent owners present evidence when seeking relief at the International Trade Commission (ITC). In a dispute over electronic stud finders, Zircon…
Read MorePatent Infringement Awards Can Disappear If Patents Are Later Found Invalid
May 2, 2024
Packet Intel. LLC v. NetScout Sys Authored by: Jeremy J. Gustrowsky A recent decision highlights a critical risk for patent owners: even after winning a patent infringement lawsuit and being awarded damages, those awards can vanish if the underlying patents…
Read MorePrinted Matter Doctrine Narrowed: Federal Circuit Clarifies Limits in Patent Disputes
May 1, 2024
IOENGINE, LLC v. Ingenico Inc Authored by: Jeremy J. Gustrowsky A recent decision from the Federal Circuit has clarified how the “printed matter doctrine” applies to modern technology patents, particularly those involving software and encrypted communications. The case centered on…
Read MoreToddler Dining Mat Patent Dispute Highlights Importance of Candor in Patent Litigation
April 12, 2024
Luv N’ Care, Ltd. v. Laurain Authored by: Jeremy J. Gustrowsky A recent decision from the Federal Circuit sheds light on the high stakes of honesty and fair play in patent lawsuits, especially when it comes to innovative products for…
Read MoreCourt Affirms Obviousness of Rifaximin Patents, Clarifies ANDA Approval Timing
April 11, 2024
Salix Pharms., Ltd. v. Norwich Pharms. Inc Authored by: Jeremy J. Gustrowsky A recent appellate decision sheds light on the complex interplay between pharmaceutical patents, generic drug approvals, and the standards for proving a patent is “obvious” in light of…
Read MoreWhen “Known” Isn’t Enough: Federal Circuit Clarifies Motivation to Combine in Patent Obviousness
March 27, 2024
Virtek Vision Int’l ULC v. Assembly Guidance Sys Authored by: Jeremy J. Gustrowsky A recent Federal Circuit decision highlights a key principle in patent law: just because two technical approaches are “known” doesn’t mean it’s obvious to combine them. The…
Read MoreJury Instruction Error on Patent Obviousness Triggers New Trial in Tamper-Resistant Container Dispute
March 27, 2024
Inline Plastics Corp. v. Lacerta Grp., LLC Authored by: Jeremy J. Gustrowsky A recent decision highlights the importance of proper jury instructions in patent cases, especially when it comes to evaluating whether an invention is “obvious” in light of earlier…
Read MoreMedical Device Importation for FDA Approval Falls Under Patent Safe Harbor
March 25, 2024
Edwards Lifesciences Corp. v. Meril Life Scis. Priv. Ltd Authored by: Jeremy J. Gustrowsky A recent decision clarified how the “safe harbor” provision in U.S. patent law protects companies when they import medical devices for activities related to FDA approval.…
Read More